Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

Myriad’s autoimmune unit on the block
Myriad Genetics Inc. (NASDAQ:MYGN) said it will focus on women’s health, cancer and mental health and pursue strategic alternatives for its autoimmune unit. In November on its earnings call, the company announced it is seeking alternatives for its contract research services and dermatology businesses.

ViGeneron, Biogen eye diseases gene therapy deal
ViGeneron Gmbh partnered with Biogen Inc. (NASDAQ:BIIB) to develop and commercialize adeno-associated viral (AAV) vector gene therapies against up to two undisclosed targets for inherited eye diseases using the German biotech’s engineered AAV capsids for retinal cell transduction. ViGeneron will receive an upfront payment and R&D funding, and is eligible for development, regulatory and commercial milestones plus tiered royalties. Financial details were not disclosed...